(Q35170042)

6 August 2017

1 reference

title

Clinical pharmacokinetics of aromatase inhibitors and inactivators (English)

1 reference

6 August 2017

1 reference

Per Lønning

1

1 reference

6 August 2017

language of work or name

1 reference

1 January 2003

1 reference

Clinical Pharmacokinetics

6 August 2017

published in

1 reference

6 August 2017

volume

42

1 reference

6 August 2017

issue

7

1 reference

6 August 2017

page(s)

619-631

1 reference

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

6 August 2017

cites work

1 reference

12 December 2020

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

12 December 2020

Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer

1 reference

12 December 2020

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer

1 reference

12 December 2020

Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer

1 reference

12 December 2020

A randomised trial of tamoxifen versus tamoxifen with aminoglutethimide in post-menopausal women with advanced breast cancer

1 reference

12 December 2020

Metabolism of aminoglutethimide in humans: identification of hydroxylaminoglutethimide as an induced metabolite

1 reference

12 December 2020

1 reference

12 December 2020

Quantitative determination of 4-hydroxy-4-androstene-3,17-dione (4-OHA), a potent aromatase inhibitor, in human plasma, using isotope dilution mass spectrometry

1 reference

12 December 2020

Anastrozole shows evidence of activity in postmenopausal patients who have responded or stabilised on formestane therapy

1 reference

12 December 2020

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

12 December 2020

The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers

1 reference

12 December 2020

Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*

1 reference

12 December 2020

Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?

1 reference

12 December 2020

Single-dose and steady-state pharmacokinetics of aminoglutethimide.

1 reference

12 December 2020

Development, application and comparison of an enzyme immunoassay and a high-performance liquid chromatography method for the determination of the aromatase inhibitor CGS 20,267 in biological fluids

1 reference

12 December 2020

Induction of cytochrome P450 2B1 in rat liver by the aromatase inhibitor aminoglutethimide

1 reference

12 December 2020

Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

1 reference

12 December 2020

Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma

1 reference

12 December 2020

Combination hormonal therapy involving aromatase inhibitors in the management of women with breast cancer

1 reference

12 December 2020

Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer

1 reference

12 December 2020

The effect of food on the relative bioavailability of fadrozole hydrochloride.

1 reference

12 December 2020

Randomized trial of tamoxifen versus aminoglutethimide and versus combined tamoxifen and aminoglutethimide in advanced postmenopausal breast cancer

1 reference

12 December 2020

Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide

1 reference

12 December 2020

Aromatase inhibitors and inactivators for breast cancer therapy

1 reference

12 December 2020

First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88

1 reference

12 December 2020

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

12 December 2020

Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study

1 reference

12 December 2020

Mechanisms of action of endocrine treatment in breast cancer

1 reference

12 December 2020

Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients

1 reference

12 December 2020

Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men

1 reference

12 December 2020

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

1 reference

12 December 2020

Determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma by reversed-phase liquid chromatography

1 reference

12 December 2020

Phase I and endocrine study of exemestane (FCE 24304), a new aromatase inhibitor, in postmenopausal women

1 reference

12 December 2020

Aromatase inhibitors in the treatment of advanced breast cancer

1 reference

12 December 2020

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

HPLC enantiomeric resolution of novel aromatase inhibitors on cellulose- and amylose-based chiral stationary phases under reversed phase mode

1 reference

12 December 2020

The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients

1 reference

12 December 2020

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

12 December 2020

High-performance liquid chromatographic assay for simultaneous estimation of aminoglutethimide and acetylaminoglutethimide in biological fluids

1 reference

12 December 2020

In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer.

1 reference

12 December 2020

Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Swiss Group for Clinical Cancer Research (SA

1 reference

12 December 2020

Radioimmunoassay of the anti-cancer agent 4-hydroxyandrostenedione in body fluids

1 reference

12 December 2020

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

12 December 2020

Dose proportionality and population characteristics of oral fadrozole hydrochloride, an aromatase inhibitor, in postmenopausal women

1 reference

12 December 2020

Breast tumor aromatase: functional role and transcriptional regulation

1 reference

12 December 2020

Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.

1 reference

12 December 2020

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer

1 reference

12 December 2020

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer

1 reference

12 December 2020

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients

1 reference

12 December 2020

Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone.

1 reference

12 December 2020

Aminoglutethimide enzyme induction: pharmacological and endocrinological implications

1 reference

12 December 2020

Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multiinstitutional trials

1 reference

12 December 2020

Determination of 4-hydroxyandrost-4-ene-3,17-dione metabolism in breast cancer patients using high-performance liquid chromatography-mass spectrometry

1 reference

12 December 2020

The effect of acetylator phenotype on the disposition of aminoglutethimide

1 reference

12 December 2020

Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio

1 reference

12 December 2020

Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor

1 reference

12 December 2020

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

12 December 2020

Concentrations of oestrone and 4-hydroxyandrostenedione in malignant and normal breast tissues

1 reference

12 December 2020

Antiaromatase agents: preclinical data and neoadjuvant therapy.

1 reference

12 December 2020

Measurement of Aromatisation by a Urine Technique Suitable for the Evaluation of Aromatase Inhibitorsin Vivo

1 reference

12 December 2020

The potential for aromatase inhibition in breast cancer prevention

1 reference

12 December 2020

Absolute bioavailability of letrozole in healthy postmenopausal women

1 reference

12 December 2020

Treatment with formestane alone and in combination with aminoglutethimide in heavily pretreated breast cancer patients: clinical and endocrine effects

1 reference

12 December 2020

Systemic therapy in breast cancer: efficacy and cost utility

1 reference

12 December 2020

Determination of the new aromatase inhibitor CGS 16 949 in biological fluids by capillary gas chromatography/mass spectrometry

1 reference

12 December 2020

Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

1 reference

12 December 2020

Liquid-chromatographic determination of aminoglutethimide in plasma

1 reference

12 December 2020

Inhibition of human drug metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase

1 reference

12 December 2020

Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).

1 reference

12 December 2020

In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients

1 reference

12 December 2020

Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection

1 reference

12 December 2020

Pharmacokinetics and metabolism of formestane in breast cancer patients

1 reference

12 December 2020

Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer

1 reference

12 December 2020

Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer

1 reference

12 December 2020

Tamoxifen and aminoglutethimide in advanced breast cancer

1 reference

12 December 2020

Polymorphically acetylated aminoglutethimide in humans

1 reference

12 December 2020

Metabolism of aminoglutethimide in humans. Identification of four new urinary metabolites.

1 reference

12 December 2020

Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers

1 reference

12 December 2020

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group

1 reference

12 December 2020

LC-MS-MS determination of exemestane in human plasma with heated nebulizer interface following solid-phase extraction in the 96 well plate format

1 reference

12 December 2020

A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer

1 reference

12 December 2020

Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure.

1 reference

12 December 2020

Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells

1 reference

12 December 2020

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

12 December 2020

Cross-resistance to different aromatase inhibitors in breast cancer treatment

1 reference

12 December 2020

Determination of aminoglutethimide and N-acetylaminoglutethimide in human plasma by high-performance liquid chromatography

1 reference

12 December 2020

Pharmacokinetics of anastrozole in Chinese male volunteers.

1 reference

12 December 2020

Arimidex: a potent and selective fourth-generation aromatase inhibitor

1 reference

12 December 2020

Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route

1 reference

12 December 2020

Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.

1 reference

12 December 2020

Single dose pharmacokinetics of aminoglutethimide by a rapid SIM methodology

1 reference

12 December 2020

Influence of aminoglutethimide on plasma levels of medroxyprogesterone acetate: its correlation with serum cortisol

1 reference

12 December 2020

Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial

1 reference

12 December 2020

Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients

1 reference

12 December 2020

Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate.

1 reference

12 December 2020

Serum Aminoglutethimide Levels: Studies of Serum Half-Life, Clearance, and Patient Compliance

1 reference

12 December 2020

Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third-generation aromatase inhibitor vorozole

1 reference

12 December 2020

Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma

1 reference

12 December 2020

Comparison of the selective aromatase inhibitor formestane with tamoxifen as first-line hormonal therapy in postmenopausal women with advanced breast cancer

1 reference

12 December 2020

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

1 reference

12 December 2020

Metabolism of aminoglutethimide in the rat

1 reference

12 December 2020

Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration.

1 reference

12 December 2020

The pharmacodynamic inhibition of estrogen synthesis by fadrozole, an aromatase inhibitor, and its pharmacokinetic disposition

1 reference

12 December 2020

Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women

1 reference

12 December 2020

Direct liquid chromatographic resolution of racemic aminoglutethimide and its acetylated metabolite using a chiral alpha 1-acid glycoprotein column

1 reference

12 December 2020

Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group

1 reference

12 December 2020

Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment.

1 reference

12 December 2020

Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression

1 reference

12 December 2020

High-performance liquid chromatography of the aromatase inhibitor, letrozole, and its metabolite in biological fluids with automated liquid-solid extraction and fluorescence detection.

1 reference

12 December 2020

10.2165/00003088-200342070-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

6 August 2017

1020703532

0 references

1 reference